Racial and Regional Differences in Gastric Cancer Immunotherapy Outcomes Explored

Advanced gastric cancer faces a grim prognosis, with a 5-year overall survival rate often falling below 10%. For previously untreated HER2-negative disease, combined chemotherapy and PD-1/PD-L1 inhibitors represent the standard first-line care. Intriguingly, clinical trials and subgroup analyses have consistently indicated that Asian patients often demonstrate stronger antitumor responses and improved survival outcomes compared to non-Asian patients. The precise reasons behind these observed differences are not fully understood, highlighting a critical area for further investigation.

A recent review, published in Cancer Biology & Medicine, sought to shed light on these variations. Researchers from The Fifth Medical Center of the Chinese PLA General Hospital and MSD China collaborated to examine racial and regional differences in first-line immunotherapy outcomes for advanced HER2-negative gastric cancer.

The review meticulously explored how various factors, including tumor biology, host immunity, infection patterns, and environmental exposures, may contribute to the distinct outcomes observed across different patient populations.

Evidence from Major Clinical Studies

The authors systematically analyzed evidence drawn from several major clinical studies, including KEYNOTE-062, CheckMate-649, KEYNOTE-859, ORIENT-16, KEYNOTE-590, and RATIONALE-305. A consistent finding across these extensive datasets was the demonstration of a greater survival benefit for Asian patients receiving immunotherapy.

The review delved into several potential contributing factors that could explain these observed disparities:

• Age and Detection: Asian patients are frequently diagnosed at a younger age. Furthermore, the presence of comprehensive screening programs in some Asian countries may contribute to earlier detection, often leading to a lower tumor burden at diagnosis.
• Tumor Characteristics: Non-Asian patients commonly present with proximal or diffuse-type disease. These specific tumor types may exhibit less favorable responses to treatment, indicating potential differences in tumor location and histology across populations.
• Molecular Subtypes: Distinct variations in mutation frequencies, affecting genes such as APC, ARID1A, KMT2A, and PIK3CA, exist across different populations. Immunotherapy-responsive subtypes, like MSI (microsatellite instability) and EBV-positive (Epstein-Barr virus-positive) tumors, appear to be more common in some Asian cohorts. Conversely, CIN (chromosomal instability) and genomically stable tumors are noted to be more prevalent in some Western populations.
• Immune and Microbiome Factors: Differences in immune signaling pathways and the composition of the host microbiome were also highlighted. This suggests that the ultimate treatment response is a result of a complex interplay between the tumor's genetic makeup and the host's unique biological environment.

Implications for Treatment and Research

The review underscores a crucial point: gastric cancer immunotherapy outcomes are influenced by a multifaceted array of interacting determinants. These include population-level differences in somatic mutations, the composition of molecular subtypes, specific aspects of tumor immunity, and varying microbial exposures. Understanding these intricate mechanisms is paramount, as it could facilitate the identification of improved biomarkers and ultimately guide more individualized treatment decisions for diverse patient populations worldwide.

The authors strongly suggest that future clinical trials should integrate ethnicity or geography into their study design, biomarker analysis, and therapeutic decision-making processes.

They also advocate for extensive translational research, emphasizing the need to combine genomics, immune profiling, and microbiome studies, alongside innovative model systems like organoids and patient-derived xenografts. This comprehensive approach implies that the efficacy of a given treatment regimen may vary across different populations and offers a robust framework for developing more precise and globally applicable immunotherapy strategies for advanced gastric cancer.